|Bid||89.91 x 60000|
|Ask||90.10 x 60000|
|Day's Range||88.93 - 89.78|
|52 Week Range||57.79 - 100.00|
|PE Ratio (TTM)||22.54|
|Forward Dividend & Yield||3.11 (3.59%)|
|1y Target Est||N/A|
The U.S spent 60 percent more on drugs for Medicare patients in 2016 than it did in four years earlier, according to newly released federal data, countering pharmaceutical industry arguments that prescription medicine represents only a small and stable portion of health-care costs. Unit costs for AbbVie Inc.’s Humira, a blockbuster rheumatoid arthritis drug, rose at an average pace of 18 percent a year during the same period, according to the figures released Tuesday by the Trump administration. The government disclosed the information as part of an updated dashboard that includes information on annual drug-price increases for several federal programs, including Medicare, for the elderly, and Medicaid, which covers the poor.
Earnings are in focus this week with Pfizer (PFE) and Merck (MRK) delivering mixed Q1 numbers. Novartis gains FDA approval for the second indication of its CAR-T therapy, Kymriah.
By David Bautz, PhD NASDAQ:NBIX INGREZZA® Launch Continues to go Well On April 30, 2018, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced financial results for the first quarter of 2018 and provided ...
The most expansive look at the issue this earnings season came from AbbVie Inc. (ABBV) Chief Executive Richard Gonzalez, who spoke at length about the new policies on the company’s first-quarter call last Thursday. The new programs, called co-pay accumulators, prevent patients from using drugmaker coupons to reduce their out-of-pocket costs. Read: Drug companies are beginning to wake up to this new risk factor and Like using that drug coupon?
Stocks that moved substantially or traded heavily Tuesday: Tapestry Inc., down $6.31 to $47.46 The company's Kate Spade and Stuart Weitzman brands had a weak first quarter. AbbVie Inc., up $5.52 to $102.07 ...
AbbVie's hepatitis C franchise "crushed it" in the first quarter, an analyst said Thursday as it and fellow drugmaker Bristol-Myers reported strong profit.
How far off is AbbVie Inc (NYSE:ABBV) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is fairlyRead More...
AbbVie's (ABBV) Q1 earnings top estimates with revenues marginally beating the same. Sales of the company's lead marketed drug, Humira, also rise year over year.
This is an increase over its earnings per share of $1.28 from the same time last year. It also beat out Wall Street’s earnings per share estimate of $1.79 for the quarter and was good news for ABBV stock. AbbVie Inc’s net income reported in the first quarter of the year was $2.78 billion.
Sales AbbVie's drugs for hepatitis C were $919 million in the first quarter of 2018, 60% above the consensus forecasts of Wall Street analysts, helping to boost the company's earnings to $2.8 billion on sales of $7.9 billion, up 33% and 21% from last year.
With earnings season in full swing, pharma stocks got a boost today from AbbVie (ABBV), and Alexion Pharmaceuticals (ALXN), although Bristol-Myers Squibb (BMY) has given up its early gains. AbbVie said ...
AbbVie's (ABBV) first-quarter 2018 earnings surpassed estimates with revenues marginally beating the same. Sales of its lead marketed drug Humira also increased compared to year ago figure.
On a per-share basis, the North Chicago, Illinois-based company said it had net income of $1.74. Earnings, adjusted for one-time gains and costs, came to $1.87 per share. The results beat Wall Street expectations. ...
AbbVie Inc. shares rose nearly 3% in premarket trade Thursday after the company reported first-quarter profit and revenue beats and announced plans to buy back up to $7.5 billion in shares. Adjusted earnings-per-share were $1.87, compared with the FactSet consensus of $1.79. Revenue rose to $7.93 billion from $6.54 billion, compared with the FactSet consensus of $7.60 billion.